Free Trial
OTCMKTS:SARTF

Sartorius Q1 2025 Earnings Report

Sartorius logo
$217.65 0.00 (0.00%)
As of 06/11/2026

Sartorius EPS Results

Actual EPS
$1.28
Consensus EPS
$1.28
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Sartorius Revenue Results

Actual Revenue
$959.23 million
Expected Revenue
$867.08 million
Beat/Miss
Beat by +$92.15 million
YoY Revenue Growth
N/A

Sartorius Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sartorius' next earnings date is estimated for Thursday, July 23, 2026, based on past reporting schedules.

Conference Call Resources

Sartorius Earnings Headlines

How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insiders and institutional holders have been sitting on positions for years and will exit the moment shares hit the market. Lance Ippolito has identified five stocks directly positioned to benefit from the SpaceX launch and the space investing wave it triggers, without the brutal IPO volatility. These picks carry none of the hype risk and all of the tailwind.tc pixel
See More Sartorius Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sartorius? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sartorius and other key companies, straight to your email.

About Sartorius

Sartorius (OTCMKTS:SARTF) AG, trading in the U.S. over the counter under the symbol SARTF, is a Germany-based provider of laboratory and bioprocessing equipment for the pharmaceutical, biotechnology and research industries. The company is organized into two core divisions: Bioprocess Solutions, which focuses on single-use consumables, filtration technologies and upstream and downstream processing systems; and Lab Products & Services, which supplies laboratory instruments, consumables and services, including balances, pipettes, cell counting systems and water purification units.

The Bioprocess Solutions segment serves customers engaged in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies. Its product range includes single-use bioreactors, tangential flow filtration systems, media and buffer preparation tools and process analytics. In the Lab Products & Services segment, Sartorius offers high-precision laboratory balances, pipetting devices, lab filtration products and software-driven services aimed at improving workflow efficiency and data integrity in quality control and R&D laboratories.

Founded in 1870 in Göttingen, Germany, Sartorius has expanded its global footprint with production and service sites across Europe, North America and Asia. The company supports research institutions, contract development and manufacturing organizations (CDMOs) and major pharmaceutical manufacturers in over 100 countries. Its executive board is chaired by Dr. Joachim Kreuzburg, under whose leadership Sartorius has pursued both organic growth and strategic acquisitions to strengthen its technology portfolio and international presence.

View Sartorius Profile